ADPKD

View All

Pharma News for XORTX, Roche, Lantheus, Janssen, Daiichi Sankyo, bluebird bio, and POINT Biopharma Global
Janssen’s AKEEGA Approval; FDA Approves Roche’s Polivy Combo for Frontline B-cell Lymphoma; Daiichi Sankyo’s Quizartinib for Adults With FLT3-ITD-Positive AML; bluebird bio BLA for lovo-cel for Patients with Sickle Cell Disease; Fast Track Designation for Lu-PNT2002 for mCRPC Treatment; FDA Orphan Drug Designation to XORTX’s Oxypurinol

Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) had granted marketing authorization for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form...

Find More

adpkd-treatment-outlook
Advancing Therapeutic Outlook for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Treatment

Key Highlights The US approval of Jynarque added the much-needed push to the ADPKD treatment market.In the coming years, Bardoxolone methyl is expected to be an effective therapy for ADPKD treatment.The current ADPKD treatment only aims to delay the disease progression rather than completely cure the disease, wh...

Find More